Share on StockTwits

Sangamo Biosciences (NASDAQ:SGMO) CEO Edward O. Lanphier II sold 25,000 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $16.41, for a total transaction of $410,250.00. Following the completion of the sale, the chief executive officer now directly owns 295,000 shares in the company, valued at approximately $4,840,950. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Sangamo Biosciences (NASDAQ:SGMO) traded down 2.39% during mid-day trading on Wednesday, hitting $16.33. 735,179 shares of the company’s stock traded hands. Sangamo Biosciences has a one year low of $6.86 and a one year high of $24.69. The stock has a 50-day moving average of $13.80 and a 200-day moving average of $16.27. The company’s market cap is $1.110 billion.

Sangamo Biosciences (NASDAQ:SGMO) last released its earnings data on Tuesday, May 6th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.13) by $0.01. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $6.59 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The company’s quarterly revenue was up 76.1% on a year-over-year basis. Analysts expect that Sangamo Biosciences will post $-0.29 EPS for the current fiscal year.

Sangamo BioSciences, Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (NASDAQ:SGMO)-binding proteins (ZFPs), a naturally occurring class of proteins.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.